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Abstract
This report summarizes the symposium, ‘Immunotherapy Biomarkers 2016: Overcoming the Barriers’, which was
held on April 1, 2016 at the National Institutes of Health in Bethesda, Maryland. The symposium, cosponsored by
the Society for Immunotherapy of Cancer (SITC) and the National Cancer Institute (NCI), focused on emerging
immunotherapy biomarkers, new technologies, current hurdles to further progress, and recommendations for
advancing the field of biomarker development.
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Introduction
Dr. James L. Gulley and Dr. Lisa H. Butterfield opened
the meeting with an introduction. The field of cancer
immunotherapy has enjoyed unprecedented successes
due to positive and durable clinical trial outcomes, the
development of new drugs, biologics and combination
therapies, and the approval of immunotherapeutics such
as immune checkpoint inhibitors. Despite this progress,
the current patient response rates and toxicities associ-
ated with immunotherapies have created a sense of ur-
gency to determine which patients would most benefit
from the treatment option. The identification of immune
biomarkers will help to fill knowledge gaps by providing
valuable predictive and prognostic information, and in-
sights on the mechanisms that underlie patient re-
sponses or resistance to immunotherapy. This would
allow development of treatment plans specific to each
patient, which could help avoid selection of ineffective
therapies, toxicities, and the resulting need to treat these
toxicities. Furthermore, the rational design of combin-
ation therapies only becomes possible once mechanisms
of action and resistance are fully elucidated.
Among current hurdles to the identification and devel-
opment of clinically relevant biomarkers is the lack of
standardized conditions for the collection and storage of
specimens. Indeed, the data obtained from variably
banked specimens are inconsistent, and at present, many
trials bank only non-viable tumor and/or serum samples.
The costs associated with immune assays can also be
prohibitive, as robust and reproducible signals cannot be
obtained by testing small numbers of samples, and at-
tempts to keep costs low by focusing on one or two ‘best
guess’ assays could lead investigators to miss the most
accurate biomarker.
The availability of novel technologies and high
throughput approaches (e.g. mass cytometry, whole ex-
ome sequencing, gene expression profiling, TCR diver-
sity, epigenetics, etc.) offers unique opportunities and
challenges for the field of biomarker development.
Through the use of these powerful techniques, a multi-
tude of questions can be addressed with a single sample,
yet the resulting quantity and complexity of data require
unique analytical considerations. The field of immune
monitoring is also influenced by the discovery that meta-
bolic considerations, the microbiome, and signaling
pathway modulation all affect the immune system. In-
deed, many standard of care therapies are now known to
operate through immune mechanisms.
* Correspondence: butterfieldl@upmc.edu
21Department of Medicine, Surgery and Immunology, University of
Pittsburgh Cancer Institute, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gulley et al. Journal for ImmunoTherapy of Cancer  (2017) 5:29 
DOI 10.1186/s40425-017-0225-6
The SITC Biomarkers Task Force was convened to ad-
dress the current state of the field, and recommend ave-
nues for progress. The ‘Immunotherapy Biomarkers
2016: Overcoming the Barriers’ symposium focused on
outcomes of topics addressed by four Task Force Work-
ing Groups. Divided between working groups (WGs),
the following themes were discussed: Immune monitor-
ing, assay standardization and validation (WG1); New
developments in biomarker assays and technologies
(WG2); Systematic assessment of immune regulation
and modulation (high throughput approaches) (WG3);
and Baseline immunity, tumor immune environment
and outcome prediction (WG4). This report summarizes
the outcomes from the meeting.
Immunologic monitoring, assay standardization
and validation (WG1)
WG1 was introduced by Dr. Magdalena Thurin. Putative
biomarkers predictive of response to immunotherapy
must undergo high quality and rigorous validation. As a
result, very few biomarkers are approved as clinically use-
ful. A major hurdle is that immune modulation affects
many cell types and complex interactions while many
drugs and small molecule inhibitors target single proteins
or pathways. Greater understanding of the complexity of
the validation process, especially for markers based on im-
mune response, is needed in order to build up the re-
sources available for immune monitoring. The two
volume white papers from WG1, in which the analytical
and clinical validation process, and regulatory consider-
ations are discussed in depth, have been published [1, 2].
Dr. Alessandra Cesano presented an overview of the
challenges faced in translating biological data into pre-
dictive biomarkers and described the example of Pro-
signa as a cleared diagnostic. A combination of factors
from the host, cancer cells, and tumor microenviron-
ment (TME), including the microbiome, shape interac-
tions between the tumor and the immune system. This
presents various hurdles, the first being the complexity
of integrating these interactions with an informative ana-
lyte (DNA, RNA, and proteins) to yield a multivariate,
multi-analyte assay. Although tens of thousands of
markers in the GVK Biosciences (GVK Bio) Online Clin-
ical Biomarker Database (GOBIOM) developed in col-
laboration with the U.S. Food and Drug Administration
(FDA) have been identified, only a fraction of these have
been developed into validated genomic biomarkers for
FDA-approved drugs, and none have become multiplex,
in vitro companion diagnostics. For a predictive bio-
marker to be applied in the clinic, it must have analytic
(the ability to accurately and reliably measure analytes of
interest in clinical specimens representative of the target
population) and clinical validity, in addition to clinical
utility. Multiple organizations have published guidelines
for the validation of diagnostic tests, with recommenda-
tions regarding analytic sensitivity, specificity, reproduci-
bility, and assay robustness [3, 4]. Dr. Cesano suggested
that the co-development of drugs and companion diag-
nostics could address the biomarker deficiency. Al-
though such an approach would increase the complexity
of drug development, it may make the process more suc-
cessful, and has great potential value for patients and
health system resource utilization.
Dr. Ilan Kirsch detailed the capabilities of high-
throughput PCR-based sequencing technology for T cell
receptor (TCR) clonality assessment. The basis of this
technology arose from the fact that the genes that en-
code functional immune receptors initially exist in germ-
line DNA as a number of discrete, non-contiguous
segments (variable, V, diversity, D, and joining, J). As a
prerequisite to the formation of a functional immune re-
ceptor, a site-specific DNA breakage and rejoining event
occurs that unifies any combination of these segments
into a contiguous V(D)J region, which encodes the hy-
pervariable part of the immune receptor. The assay uses
forward primers from the V segments, and reverse
primers from the J segments, to amplify and then se-
quence the area of this rearrangement event, thus creat-
ing a unique “barcode” of the lymphocyte and all clonal
progeny of the rearranged cell. In this way, immunose-
quencing can quantify and specify every B and/or T cell
in a sample of interest with a high degree of sensitivity
and reproducibility. The superior accuracy of immuno-
sequencing has been demonstrated in side-by-side com-
parisons with multi-parameter flow cytometry, in which
immunosequencing successfully detected minimal re-
sidual disease in samples from patients with both T and
B cell hematologic malignancies that were missed by
flow cytometric techniques [5]. Additional applications
of high-throughput clonality assessment include insights
into drug mechanisms, measurements of immune sys-
tem dynamics, and prognostic potential. In a study using
immunosequencing to assess the number and clonality
of tumor-infiltrating lymphocytes (TIL) from tissue sam-
ples of stage II DNA mismatch repair-proficient colon
cancer patients, it was found that patients with below-
median clonality and TIL number were at higher risk for
disease recurrence [6]. This type of TIL assessment also
may predict response to therapy. When applied to the
setting of melanoma, patient samples with TIL beneath
the median number and level of clonality were less likely
to respond to anti-PD-1 therapy [7].
Dr. Sylvia Janetzki discussed challenges associated with
single cell functional immune assay validation. The inher-
ent variability associated with assays such as ELISPOT and
intracellular cytokine staining [8], due to either the assay it-
self or due to the sample, needs to be considered. Sample
quality must be addressed in pre-analytical validation and
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many guidelines already exist regarding peripheral blood
mononuclear cell (PBMC) processing [9], avoidance of
granulocyte contamination, apoptosis assessment, and over-
night resting of samples. Assay variability arises from the
lack of standardized protocols as well as the absence of a
“gold standard”, which makes accuracy impossible to deter-
mine. To address the issue of assay variability, participation
in proficiency panels [10] is recommended, as they provide
an analysis of one’s own measurement in relation to
measurements from many other groups in the field using
many different protocols. Open proficiency panel programs
already exist for ELISPOT and multimer panels and are
available to all labs on a non-profit basis. In addition to
evaluating the relative accuracy of data, proficiency panels
can be used to identify critical protocol variables that are
predictive of assay performance. These critical variables
have been collected and summarized in published
harmonization guidelines to be used by labs for
optimization of assay outcomes [11], and are now available
for ELISPOTassay and analysis, multimer staining, intracel-
lular cytokine staining (ICS) assay, and gating. Finally, as
precision is the most important parameter to ensure confi-
dence in data analysis, intra-assay, inter-assay, and inter-
operator precision need to be demonstrated in the form of
repeatable results with a low false positive rate once assays
have been harmonized.
Dr. Shyam Kalavar from the U.S. FDA presented on regu-
latory considerations for in vitro diagnostic devices in can-
cer immunotherapy. Companion in vitro diagnostic (IVD)
devices provide information that is essential for the safe
and effective use of a corresponding therapeutic product
(e.g. PD-L1 IHC 22C3 pharmDx diagnostic test manufac-
tured by Dako A/S (now Agilent Technologies)). In con-
trast, complementary diagnostics are tests that identify a
biomarker-defined subset of patients that is expected to re-
spond particularly well to a drug, and aid risk/benefit as-
sessments for individual patients, but are not pre-requisites
for receiving the drug (i.e., are not companion diagnostics).
An example of a complementary IVD device is PD-L1 IHC
28–8, manufactured by Dako A/S (now Agilent Technolo-
gies) for non-squamous NSCLC and melanoma. As
commercialization of IVD requires FDA clearance, a key
regulatory question is whether adequate analytical and clin-
ical performance data are available to be approved contem-
poraneously with the drug approval. In the case of
immunohistochemistry-based assays such as PD-L1 IHC
22C3, analytical validation studies include biochemical
characterization of the antibody, tests of assay sensitivity
and specificity, precision, inter-laboratory reproducibility,
assay robustness, the impact of pre-analytical variables, sta-
bility, and control cell line validation. Additional informa-
tion regarding IVD regulation is available in guidance
documents provided by the FDA to help direct validation
of such devices.
Each section of the meeting had time for a panel dis-
cussion. The speakers addressed several questions, in-
cluding those relating to publication of assay details for
proper evaluation by the field.
New developments in biomarker assays and new
technologies (WG2)
Dr. Jianda Yuan introduced the WG2 areas of focus. Over
the past year, the members of Biomarkers WG2 have col-
laborated to evaluate new technologies. These include
quantitative real-time PCR-assisted cell counting (qPACC)
[12], protein microarray (‘seromics’) [13], flow and mass
cytometry [14], multiplexed tissue biomarker imaging
[15], and whole exome sequencing for mutation load/
neoantigen discovery [16]. All the resulting papers have
been published in the Journal for ImmunoTherapy of
Cancer (JITC) technology primer series [17–23], with still
more on the horizon. Additionally, the WG2 white paper
highlights novel technologies and emerging biomarkers
relevant to individualized cancer immunotherapy, with
recommendations for best practices unique to each [24].
As the prognostic power of TILs continues to gain wide-
spread recognition [25, 26], Dr. Bernard A. Fox believes
that multispectral imaging is critical to advancing our un-
derstanding of the complex interactions in the TME.
Using markers of immune cell subsets, phenotype, and
function [27], standardized multispectral immunohisto-
chemistry is ideally suited to address interactions between
multiple parameters, especially when patient sample avail-
ability is a consideration. However, difficulties associated
with this technique include high background fluorescence,
availability of antibodies, photobleaching, and image
analysis [28]. The development of a tyramide signal ampli-
fication reagent was a breakthrough in multispectral tech-
nology that obviates such issues. This technique was used
to interrogate tumors from a cohort of patients with mel-
anoma to determine that the CD8:FoxP3 ratio predicts
ability to generate TIL, the predictive power for which in-
creases with the addition of PD-L1 [29]. The examination
of multiple parameters thus offers value compared to sin-
gle parameter analysis in a complex environment where
ratios, relative positions, and functional analyses are
mechanistically important. Dr. Fox suggested that ad-
vancements in multispectral imaging technology could
provide support for stratification of patients for clinical
trials in the future.
Dr. Jianda Yuan described how next-generation sequen-
cing technologies such as whole exome sequencing are pav-
ing the way for precision oncology. Mutation-derived
antigens (neoantigens) have long been an area of research
interest, but the patient-specific nature of neoantigens rep-
resented a hurdle to the broader application of these data
for a therapeutic purpose. The advent of whole exome se-
quencing has allowed for a comprehensive description of
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the mutation load, termed the “mutational landscape”,
which has been a valuable resource to the field of immuno-
therapy, since neoantigen immunogenicity has been shown
to be a correlate of response to treatment. For example,
neoantigen-specific T cell reactivity was demonstrated via
tumor exome sequencing in ipilimumab-responsive melan-
oma [30], and most patients who responded to ipilimumab
treatment had a relatively high mutation load [31]. Simi-
larly, the nonsynonymous mutation burden was associated
with clinical benefit of anti-PD-1 therapy in patients with
NSCLC [32], and MMR deficiency in colorectal cancer cor-
related with better clinical response to PD-1 blockade [33].
Potential uses of whole exome sequencing for neoantigen
discovery and precision oncology include: prediction of
patient response to vaccine and cancer immunotherapy,
identification of new targets, therapeutic neoantigen vaccin-
ation, adaptive neoantigen T cell transfer therapy, and the
design of effective combination immunotherapies. Strat-
egies to move the field forward include combining ap-
proaches that integrate function (e.g. ELISPOT), phenotype
(e.g. multicolor flow cytometry), and signature (e.g. whole
exome sequencing, gene expression profile).
Dr. Holden Maecker spoke of the need to systematically
measure immunocompetence in cancer patients, as trad-
itional radiation and chemotherapy can be immunosup-
pressive, and immunotherapeutic agents interact directly
with the immune system. Such an assessment of circulat-
ing immune subsets and functions could be prognostic of
an overall response or a response to specific agents [34].
Mass cytometry (CyTOF) is a powerful alternative to
fluorescence flow cytometry that can simultaneously as-
sess multiple parameters with little to no spillover be-
tween channels. Dr. Maecker described two studies that
employed the use of CyTOF technology to interrogate the
immune systems of cancer patients at various time points,
both of which suggested that specific immune profiles
may be prognostic for response to immunotherapy. In
particular, the presence of CD8+ central memory T cells
and/or IL-2-producing T cells were associated with re-
sponse to treatment. This immune profile may be a com-
mon predictor across multiple chronic conditions, as lack
of CD8+ T cells that make IL-2 has been associated with
disease progression in HIV [35]. The mTOR pathway
might represent a means of boosting the central memory
compartment in order to improve response rates for im-
munotherapies, as mTOR inhibition has been shown to
reduce PD-1 expression and increase central memory T
cells [36, 37].
Multifaceted immunomonitoring techniques to identify
biomarkers predictive of clinical outcome were addressed
by Dr. Cristina Maccalli. To capture the complexity of
tumor-immune cell interactions, a multifaceted approach
integrates different techniques for assessing immune
cell phenotypes, functional capabilities, and negative
immunoregulatory factors within the same patient sample.
Such an approach was applied in a multicenter, controlled
study of patients with melanoma being treated with an
anti-CTLA-4 agent plus chemotherapy [38, 39]. Initially,
standardized multiparameter flow cytometry was used for
phenotype analysis of peripheral blood mononuclear cells
(PBMC) to identify different subsets of T cells, NK cells,
and B cells both at baseline and treatment. Soluble serum
factors such as secreted natural killer group 2D (NKG2D)
receptor ligands, which are upregulated in tumor cells and
can impair T cell responses were also measured. These
data were integrated with classification and regression
trees (CART) and an interesting finding emerged, in
which patients with longer overall survival were lacking
the soluble ligand and had an increase in the frequency of
CD4+ BTLA+ memory T cells and Th17-like cells at base-
line. Further investigation with functional assays revealed
a correlation between antigen-specific T cell responses
and clinical outcomes [40]. Thus, multifaceted immuno-
monitoring platforms can help identify a functional im-
munological signature predictive of clinical outcome to
immunotherapy, although this platform needs to be opti-
mized and validated with a large cohort of patients under-
going immunotherapy treatments. Dr. Maccalli concluded
by stating that the contemporaneous analysis of tumor
and peripheral blood could define whether i) a specific
tumor immunophenotype is characterized by a distinct
peripheral blood gene signature and ii) those signatures
correlate with clinical outcome. If it proves that gene sig-
natures correlate with a peripheral blood cell subset
phenotype, this would allow a detailed characterization of
specific immunophenotype associated with patients’ clin-
ical outcome.
The WG2 section had a panel discussion with the
speakers. Topics discussed included the timing of sample
testing, analysis of primary tumors and metastases, and
the extent to which technologies and approaches can be
prioritized based on existing data.
Assessment of immune regulation and
modulation systematically (high throughput
approaches) (WG3)
Dr. David F. Stroncek presented the areas focused on by
the third WG. WG3 sought to provide guidance on which
tissue sources should be considered for analysis and moni-
toring during the process of clinical trial design. Sample
materials discussed included serum/plasma, peripheral
blood leukocytes, and the microbiome (a focus of the WG3
white paper). In addition, the means by which the tissue
should be evaluated, such as proteomics, flow cytometry,
gene expression, micro RNA expression, and mutation ana-
lysis approaches were considered, along with recommenda-
tions for data analysis. Adoptive cell therapies were also
discussed. The rapid evolution of the science, and of
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analytical methods, as well as the very large quantities of
data involved, present challenges to developing state-of-
the-art guidance [41].
Dr. Peter P. Lee focused on three main aspects of the
tumor microenvironment: 1) the importance of the tumor
microenvironment to clinical outcomes, 2) the equal im-
portance of the number of cells present and the spatial re-
lationships between them, and 3) the tumor-draining
lymph nodes (TDLN), which are the major site of cancer
cell-immune cell interaction. Tumors comprise more than
cancer cells alone, since roughly 50% of human tumors
are >50% stroma. Patients with ‘stroma-rich’ tumors have
poorer clinical outcomes because stromal cells provide
growth and metabolic factors that protect cancer cells
from a variety of anti-cancer drugs, including chemothera-
peutic agents and targeted drugs such as BRAF inhibitors.
Indeed, stromal cell density appears to be an independent
prognostic marker in breast, colorectal, pancreatic, and
other cancers. As mentioned by other presenters, intratu-
moral immune cells are also predictive of clinical out-
come, which led to the Immunoscore effort [42] to aid in
clinical decision-making. The interplay between cancer
cells, immune cells, and non-immune stromal cells within
the TME can be studied using an automated quantitative
pathology imaging system. This system allows for the
identification of spatial immune cell patterns within the
tumor, which may have implications for clinical outcomes.
For example, to address whether TDLN functionality is al-
tered in cancer, immune cell populations were evaluated
in disease-free versus relapsed breast cancer patients. A
significantly higher percentage of CD4+ T cells and CD1a
+ dendritic cells (DC) was found in the draining lymph
nodes of patients who remained disease-free versus those
who had relapsed, and this immune profile alone corre-
lated with disease-free survival [43]. Spatially, DC within
lymph nodes of disease-free patients were found in clus-
ters, whereas the architecture of DC clusters from the
nodes of patients whose disease had relapsed were dis-
rupted —a pattern that also correlated with clinical out-
come [44]. Quantitative, spatial image analysis of tumors
and TDLN will be highly informative in understanding
how therapies modulate the balance between cancer and
host immune responses.
The importance of monitoring adoptive cellular therap-
ies as a means of improving clinical outcomes for patients
was presented by Dr. David F. Stroncek. Multiple studies
of tumor-infiltrating lymphocytes (TIL) as sources of au-
tologous cells for transfer in patients with melanoma have
yielded markers indicative of clinical outcome. Specifically,
higher total numbers and percent of CD8+ T cells infused
are associated with improved outcomes, as is persistence
of T cell clones post-infusion. Other markers have been
correlated with outcomes in individual studies and may
merit additional investigation, such as telomere length
and expression of CD27 [45]. Studies of CD19 CAR Tcells
in patients with lymphoma or acute lymphocytic leukemia
(ALL) have demonstrated that peak levels of CAR T cells
with a high CD8:CD4 T cell ratio, and higher numbers of
CD8+ effector T cells, are associated with a better re-
sponse [46–48]. Factors that influence high peak blood
levels of CD19 CAR T cells include the presence of CD19
+ cells at the time of infusion (lymphoma) [47] and quan-
tities of blasts in bone marrow (ALL). Dr. Stroncek also
commented on three complications associated with adop-
tive cellular therapies: tumor lysis syndrome, cytokine re-
lease syndrome (CRS), and neurotoxicity, and the use of
biomarkers to assess them. Patients with a higher tumor
burden and greater numbers of circulating CAR T cells
are more likely to experience CRS [46]. In the clinic, ele-
vated levels of IFNγ and IL-6, or C-reactive protein (CRP)
as a surrogate for IL-6, can be tested for, as markers of
toxicity [46]. Closing recommendations focused on
monitoring levels of adoptively transferred cells; analyzing
infused cells for phenotype, gene expression, and polymor-
phisms; and tracking CRP levels post-treatment.
Dr. Barbara Seliger opened the discussion about
immune monitoring of clinical trials by noting that the
primary goal of cancer immunotherapy is to increase anti-
tumor activity by activating the immune response, altering
the tumor microenvironment, and overcoming tumor-
associated barriers. In order to analyze the efficacy of
these strategies, it is necessary to integrate multiple high-
throughput technologies, which requires investigators to
obtain patient samples of peripheral blood, tumor cells,
and tumor-infiltrating cells. Ideally, samples should be col-
lected prior to, during, and after treatment, depending on
the type of immunotherapy used. Although such an ap-
proach is best suited for peripheral blood and in the set-
ting of melanoma, the discovery of links between the
immune response and the expression of immune modula-
tory molecules on tumors may present alternative ap-
proaches to monitoring. For example, a decrease in tumor
antigen expression is associated with a lack of tumor-
specific immune response, and alterations in class I anti-
gen presentation can lead to reduced effector cell cytotox-
icity. [49]. It is also important to note that certain types of
immunotherapy, including peptide vaccination, check-
point inhibitors, and adoptive T cell transfer, have been
shown to allow for the evolution of acquired resistance to
treatment by selecting for HLA class I loss variants. HLA-
G is a non-classical HLA class I molecule that is a putative
novel inhibitory checkpoint, as it is often over-expressed
in tumors, can inhibit NK and T cell mediated cytotox-
icity, and is associated with poorer prognoses in a variety
of solid tumors [50]. Dr. Seliger closed by saying that it is
important to understand the mechanisms of immune es-
cape in order to appropriately apply immunomodulatory
agents, but immune monitoring should not cease once a
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therapy has been selected. Rather, continued monitoring
is an important means of addressing resistance to treat-
ment that may emerge over time.
Ms. Janet Siebert described the current state of immune
monitoring as a compilation of “humpty dumpty data
sets” in her presentation on Analysis of the Systemic Host
Response. Her statement emphasized that contemporary
data sets are generated through interrogation of multiple
tissues, using multiple assays, from multiple organizations
(from multiple intra- or inter-institutional cores), across
academia, industry, and government. Such fragmentation
could reduce the feasibility of measuring of the systemic
response. Instead, the field needs to move toward the
compilation of integrated heterogeneous data sets or “het
sets”, which use a consistent assay-agnostic format that
spans assays, tissues, and organizations, and supports
analysis of the systemic cross-compartment response. Ad-
vantages of het sets include a common technical and con-
ceptual representation of an otherwise unwieldy data set,
the application of the same analytical tools to a large num-
ber of analytes from different assays, and the ability to
apply established multivariable analytical approaches to
the integrated whole. Ideally, these analytical approaches
would be well-established and magnitude-insensitive with
both visual and quantitative results that can be easily vali-
dated in follow-up studies. Decision tree classification is
an example of a suitable analytical approach that seeks to
determine which analytes most cleanly separate patients
into responder and non-responder groups. These can be
supplemented with reference data sets to ensure that
thresholds are not arbitrary or over-fitted. To address sys-
temic responses that span assays or tissues, linear regres-
sion modeling can be used to capture the relationship
between analyte pairs [51]. The resulting complex im-
munological data can then be synthesized with a network
arc diagram to provide succinct visualization, and insights
into underlying the biological mechanisms of interest,
such as responsiveness to therapy [52].
During the WG3 panel discussion, the speakers com-
mented on the use of high throughput technologies to
test adoptive cellular therapies, and detection of tertiary
lymphoid structures.
Prediction of clinical outcome based on baseline
measures (WG4)
Dr. Sacha Gnjatic introduced the fourth WG and its ac-
tivities. Aiming to provide recommendations on how to
predict a patient’s response to treatment through ana-
lysis of baseline biomarkers in blood and tumor, includ-
ing MDSC and other immature myeloid cells, and
checkpoint molecule expression. WG4 also focused on
the diversity of immune cells present in the TME (in-
cluding tertiary lymphoid structures), effectiveness of
peripheral surrogates of the TME, and new technologies
to aid in the comprehensive analysis of baseline immun-
ity (manuscript in revision for the Journal for Immuno-
Therapy of Cancer).
Investigations into the tumor microenvironment at a
genetic level, as presented by Dr. Samir N. Khleif, seek to
address whether genetic changes within the tumor micro-
environment can guide the design of cancer immunother-
apeutics. The power of this approach was illustrated by
investigations into Ras as a mutated antigen immune tar-
get. In contrast to prognostic or predictive biomarkers,
immune targets are biomarkers that might not correlate
strongly with response to treatment, such as PD-L1, but
can help direct the development of therapies. Dr. Khleif
described a study in which Ras mutations were used as
immune target biomarkers. Patients with advanced solid
tumors bearing Ras mutations were given a cancer vaccine
comprised of autologous peptides along with IL-2, GM-
CSF, or both. Although most patients developed antigen-
specific immune responses, only one patient out of 57
generated productive immunity that went on to eliminate
the tumor cells [53]. This disparity led to the discovery
that regulatory T cell (Tregs) are significantly expanded in
colon cancer patients with mutated Ras compared to both
healthy individuals and colon cancer patients with wild-
type Ras. It was found that mutant Ras activates the MEK-
ERK-AP1 pathway to induce secretion of high levels of IL-
10 and TGF-β1, which generate local induction of regula-
tory T cells (Treg) in the tumor microenvironment [54].
Ras mutation was noted to be an early event in the devel-
opment of tumors leading to the proliferation of affected
cells, and the resulting induction of Treg serves to support
tumor immune escape by creating a suppressive micro-
environment that inhibits the anti-tumor immune re-
sponse. Dr. Khleif suggested that an additional agent
targeting Treg could boost the efficacy of a cancer vaccine
in patients with Ras mutations. Thus mutated antigens
used as immune target biomarkers can also guide investi-
gations into immune bystander effects on the microenvir-
onment, with the potential to inform the development of
rational combination treatments.
In a forward-looking discussion, Dr. Vaios Karanikas pre-
sented on multiplex immunohistochemistry (IHC) in clinic-
ally annotated material: where are we and where are we
going? As more clinical data become available from patients
treated with cancer immunotherapies, it has become clear
that patients with inflamed tumors are more likely to re-
spond to treatment. A deeper understanding of the interac-
tions between the immune system and tumor cells within
the tumor microenvironment is needed to achieve the ul-
timate goal of designing therapeutic strategies capable of in-
flaming “cold” tumors and addressing immune escape
mechanisms. The identification of predictive and prognos-
tic biomarkers using high throughput approaches like
multiplex IHC would aid this endeavor and Dr. Karanikas
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offered a number of best practices for consideration. As
tumor cells do not develop in isolation, it is imperative to
assess the TME comprehensively (immune cells, stroma,
and tumor cells), and compare paired samples from the
same patient before, during, and after treatment. Choice of
technology, e.g., chromogenic vs immunofluorescence, and
antibody selection, can be guided by pragmatism. A rele-
vant example of the complex questions that can be ad-
dressed by multiplex IHC includes the efforts to define the
tumor-infiltrating cell types. This approach demonstrated
the prognostic value of specific subsets of immune cell infil-
trates [55, 56], their spatial distribution within the TME
[57, 58], and qualitative characteristics such as an exhausted
phenotype [7, 59]. Importantly, the integration of comple-
mentary technologies such as multiplex IHC, mutational
profiling, and gene expression patterns can overcome the
limitations of each method, as well as offer an improved
understanding of the TME toward the identification of pre-
dictive and prognostic immune biomarkers.
The identification of biomarkers in the peripheral blood
– the most readily available tissue for sampling – to assess
a patient’s response to treatment was the focus of Dr.
Marcus O. Butler’s Multiplex/Blood Profiles presentation.
Central to this approach is a need to identify whether bio-
markers in the TME are also present in the peripheral
blood. Investigations into circulating PD-1+ lymphocytes,
which have been shown to contain T cells specific for
tumor-associated antigens and neoantigens, have provided
evidence to suggest that this is possible, although such
populations of interest are less frequent in blood [60]. The
main tools available to interrogate rare cell populations in-
clude flow and mass cytometry and a number of different
computational methodologies have been published to
guide the analysis of these complex data [61]. In addition
to its utility as a window into the TME, the peripheral
compartment can be used to try to influence baseline im-
munity. One such study involved the adoptive transfer of
in vitro-activated tumor antigen-specific T cells into pa-
tients with metastatic melanoma, the result of which was
a stable increase in anti-tumor central memory cells de-
tectable in the peripheral blood [62]. Upon subsequent
treatment with anti-CTLA-4, the transferred cells ex-
panded and generated partial responses [62] that laid the
foundation for follow up studies including Adoptive Cell
Therapy InVigorated to Augment Tumor Eradication
(ACTIVATE): Cohorts 1–3.
In a discussion about B cells at the tumor site, and sys-
temic humoral responses, as predictive biomarkers, Dr.
Sacha Gnjatic noted that B cells organized in tertiary
lymphoid structures (TLS) can be identified near tumors
and the presence of dense follicular B cells along with ma-
ture DC is associated with a good prognosis in non-small
cell lung cancer (NSCLC) [63]. Taking these observations a
step further, investigators sought to determine whether the
specificity of local and circulating antibodies may reflect the
immunogenicity of the tumor. Tumor antigen-specific
humoral immunity has been previously shown to correlate
with CD4+ and CD8+ T cell responses to the cancer-testis
antigen NY-ESO-1 [64, 65], and more recent studies in pa-
tients with NSCLC have gone on to demonstrate correla-
tions between anti-NY-ESO-1 antibody titers and tumor
stage, overall survival, and clinical course following anti-
CTLA-4 immunotherapy [66, 67]. To translate humoral
immune monitoring to the clinic, a seromics approach
would allow for a sensitive and high-throughput means of
detecting alterations in the antibody repertoire as a surro-
gate for the tumor immune response. Additional work in
the area of comprehensive immune monitoring will need to
establish appropriate targets that assign functionality to
antigen specificity and relate to clinical outcomes.
The WG4 panel discussion addressed issues of tumor
acquisition, including cost, logistics, and enabling a cul-
ture of routine tissue banking at different institutions
and clinical settings.
National cancer institute perspectives on
biomarkers
In a presentation focused on lessons learned from the per-
ipheral immunoscore, Dr. Jeffrey Schlom, discussed appli-
cations for the current state of flow-based technology that
now allows for identification of 123 immune cell subsets
from one tube of blood, using 30 markers. The subsets an-
alyzed include nine standard immune cell subsets and 118
additional subsets relating to maturation and function
[68]. In particular, monitoring of multiple peripheral im-
mune subsets can aid in the identification of patients most
likely to benefit from immunotherapy. For example, one
study of patients with metastatic breast cancer treated
with chemotherapy alone or in combination with cancer
vaccine sought to use baseline measures of peripheral im-
munity to discriminate between patients with longer or
shorter PFS. Indeed, a correlation between the presence of
particular immune cells at baseline and disease progres-
sion was noted, although only in the combination therapy
arm [69]. Such peripheral immunoscore analyses are
intended to complement biopsy analyses, and can be used
in many cancer types and stages for which biopsies are
not easily obtained. Peripheral immune monitoring can
extend beyond cells to the level of antigens. Several stud-
ies have demonstrated improved clinical outcomes due to
the presence of cascade antigens (epitope spreading) fol-
lowing treatment with cancer vaccines as a result of tumor
cell lysis and subsequent cross-priming [70–74]. For ex-
ample, a trial using the cancer vaccine PROSTVAC in pa-
tients with prostate cancer revealed that a majority of
patients generated T cells that mounted an immune re-
sponse to antigens not present in the vaccine [75]. These
data indicate a means by which heterogeneity among
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tumor cells can be minimized therapeutically, and Dr.
Schlom suggested that all cancer vaccine clinical trials
should include cascade antigen analyses.
Dr. Jay A. Berzofsky discussed the utility of extracellular
vesicles (EV) as biomarkers of immune responses and
tumor responses in cancer immunotherapy. Although pre-
viously underestimated as a homogeneous population, EV
are gaining interest as diverse subsets that play many im-
munoregulatory roles in cancer. Released by both immune
cells and tumor cells, EV are 100 nm particles capable of
shuttling “packets” of information in the form of mRNA,
miRNA, and protein between cells, the effects of which
can be immunostimulatory or immunosuppressive. Simi-
lar to standard FACS technology, nanoFACS was devel-
oped to analyze, sort, and decode EV subsets based on
light scatter and fluorescence. Once sorted, the EV could
be further analyzed by molecular profiling via protein ex-
pression and RNA/DNA typing. The analysis of EV from
patient plasma samples could provide a means of
monitoring the immune response and directing treatment
decisions, and it has the potential to make both
membrane-bound and soluble (exosome-bound) TME-
specific biomarkers accessible via “liquid biopsy”.
Conclusions
In his closing remarks, Dr. James L. Gulley was optimistic
that the opportunities presented by the use of biomarkers
for immune monitoring outweighed current challenges.
Having raised awareness of potential difficulties in im-
mune biomarker research, the SITC Biomarkers Task
Force WGs have also made recommendations for how to
approach these challenges, and will continue to provide
guidance as the field develops.
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